Literature DB >> 9100350

Venous thrombolysis by tissue-type plasminogen activator in conjunction with the urokinase-fibrinogen covalent conjugate. Effects of potentiation and faster action in dogs.

A V Maksimenko1, E G Tischenko, A D Petrov, M L Petrova, V L Golubykh.   

Abstract

Conjunctive administration of the tissue-type plasminogen activator (t-PA) and the urokinase-fibrinogen covalent conjugate (UK-Fbg) was studied by the example of venous thrombosis in dogs. Comparing the effect of separate use of the two components, we observed the potentiation of thrombolytic effect induced by an i.v. bolus infusion administration of the tissue-type plasminogen activator (1 and 4 mg, respectively) combined with a bolus administration 15 min after the first injection of the 25,000 IU UK-Fbg. Faster-action and potentiation effects of thrombolysis were observed with the same administration scheme when the t-PA was used as bolus infusion (1 and 1 mg, respectively) combined with a bolus of the 250,000 IU fibrinogen-modified urokinase. The findings indicate an approach to the development of efficient thrombolytic compositions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9100350     DOI: 10.1007/bf02785694

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   2.926


  9 in total

Review 1.  Plasminogen activators. The old and the new.

Authors:  M S Runge; T Quertermous; E Haber
Journal:  Circulation       Date:  1989-02       Impact factor: 29.690

2.  Fibrinogen-immobilized urokinase demonstrates increased thrombolytic activity in animal experiments.

Authors:  A V Maksimenko; M B Samarenko; A D Petrov; E G Tischenko; V P Torchilin
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

Review 3.  The plasminogen-plasmin system.

Authors:  J Henkin; P Marcotte; H C Yang
Journal:  Prog Cardiovasc Dis       Date:  1991 Sep-Oct       Impact factor: 8.194

Review 4.  Towards better thrombolytic therapy.

Authors:  D Collen; H R Lijnen; H K Gold
Journal:  Prog Cardiovasc Dis       Date:  1991 Sep-Oct       Impact factor: 8.194

Review 5.  Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase.

Authors:  V Gurewich
Journal:  Semin Thromb Hemost       Date:  1989-04       Impact factor: 4.180

6.  Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates.

Authors:  P Holvoet; M Dewerchin; J M Stassen; H R Lijnen; T Tollenaere; P J Gaffney; D Collen
Journal:  Circulation       Date:  1993-03       Impact factor: 29.690

7.  Molecular assembly of plasminogen and tissue-type plasminogen activator on an evolving fibrin surface.

Authors:  V Fleury; S Loyau; H R Lijnen; W Nieuwenhuizen; E Anglés-Cano
Journal:  Eur J Biochem       Date:  1993-09-01

8.  Optimizing the bolus/infusion ratio for intravenous administration of urokinase in dogs.

Authors:  R E Klabunde; C C Hemenway; S J Mohrman; J Henkin; S F Badylak
Journal:  Thromb Res       Date:  1988-06-15       Impact factor: 3.944

9.  Water-soluble urokinase derivatives with increased affinity to the fibrin clot.

Authors:  A V Maksimenko; V P Torchilin
Journal:  Thromb Res       Date:  1985-05-01       Impact factor: 3.944

  9 in total
  1 in total

1.  2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics.

Authors:  Claire R Sharp; Marie-Claude Blais; Corrin J Boyd; Benjamin M Brainard; Daniel L Chan; Armelle de Laforcade; Robert Goggs; Julien Guillaumin; Alex Lynch; Erin Mays; Duana McBride; Tommaso Rosati; Elizabeth A Rozanski
Journal:  J Vet Emerg Crit Care (San Antonio)       Date:  2022-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.